Media Coverage

Media Coverage

Read how Vistagen’s intention to revolutionize mental health medicine is causing a buzz in the media.

PharmaExec.com logo image
Ketamine-Like Compound Offers New Hope as a Potential Antidepressant and Non-opioid Painkiller
Read
Fox Business logo image
J&J's ketamine-based drug drives sea change for new depression treatments
Read
BioWorld logo image
FDA clears J&J's esketamine in treatment-resistant depression, with restrictions as per REMS
Read
Thepharmaletter logo image
FDA approves Spravato nasal spray for depression
Read
Cheddar logo image
Seeking a Cure: VistaGen Therapeutics' Potential Anti-Depression Drug
Read
BioSpace logo image
BioSpace's Global Biopharma Roundup: February 21
Read
Fox Business 1 logo image
J&J nears FDA approval for landmark depression drug to replace ketamine treatments
Read
Informatics logo image
Can We Treat Mood Disorders with Pharmacological Therapeutics?
Read
BioSpace logo image
Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression
Read